Immunoprecipitation-mass spectrometry reveals known and novel (NatC, BCS1L ) antinuclear antibodies in rheumatoid arthritis
Authors' conclusion
IP-MS revealed a diverse spectrum of autoantigens in patients with ANA-positive RA, including previously unreported targets.
Study context
- Population
- Antinuclear antibodies (ANA)-positive, DMARD-naïve patients with rheumatoid arthritis (RA)51 ANA-positive RA sera
- Participants
- 51 / 43 / 88
- Comparison
- ANA-positive RA vs Healthy individuals vs Systemic rheumatic disease
- ANA-positive RAn = 51
- Healthy individualsn = 43
- Systemic rheumatic diseasen = 88
- Outcome
- Known and novel autoantigens identified by IP-MS
Methodological detailsimmunoprecipitation-mass spectrometry (IP-MS), HeLa nuclear or cytoplasmic extracts
- Immunoprecipitation-mass spectrometry (IP-MS)
- HeLa nuclear or cytoplasmic extracts
Main finding
As reported in the abstract
Autoantigens detected by IP-MS in ANA-positive RA sera
Autoantigens detected, all RA samples
10 of 51
Autoantigens detected, titre 1/160
2 of 29
Autoantigens detected, titre 1/320
4 of 12
Autoantigens detected, titre ≥1/640
4 of 10
Further findings
- Neither NatC nor BCS1 detected in healthy individuals or individuals with other systemic rheumatic diseases
Original publication
Immunoprecipitation-mass spectrometry reveals known and novel (NatC, BCS1L ) antinuclear antibodies in rheumatoid arthritis. RMD Open. Published 10 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →